- Companies
- Lumos Diagnostics Hldgs
Lumos Diagnostics Hldgs Valuation Multiples
Lumos Diagnostics Hldgs is valued at $67M as of October 2026, a 3.8x revenue multiple. In the last 12 months, Lumos Diagnostics Hldgs revenue was $15M and Lumos Diagnostics Hldgs EBITDA was ($6M).
Lumos Diagnostics Hldgs Overview
About Lumos Diagnostics Hldgs
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
Founded
2018
HQ
Employees
110
Website
Financials (LTM)
EV
$58M
Valuation Multiples
Start free trialLumos Diagnostics Hldgs Financials
Lumos Diagnostics Hldgs reported last 12-month revenue of $15M and negative EBITDA of ($6M).
In the same LTM period, Lumos Diagnostics Hldgs generated $9M in gross profit, ($6M) in EBITDA losses, and had net loss of ($6M).
Revenue (LTM)
Lumos Diagnostics Hldgs P&L
In the most recent fiscal year, Lumos Diagnostics Hldgs reported revenue of $13M and EBITDA of ($412K).
Lumos Diagnostics Hldgs is unprofitable as of last fiscal year, with gross margin of 60%, EBITDA margin of (3%), and net margin of (38%).
Financial data powered by Morningstar, Inc.
Lumos Diagnostics Hldgs Stock Performance
Lumos Diagnostics Hldgs has current market cap of $67M, and enterprise value of $58M.
Market Cap Evolution
Lumos Diagnostics Hldgs' stock price is $0.07.
Lumos Diagnostics Hldgs share price decreased by 1.0% in the last 30 days, and by 48.3% in the last year.
Lumos Diagnostics Hldgs has an EPS (earnings per share) of $-0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $58M | $67M | -0.0% | -1.0% | -0.9% | -48.3% | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLumos Diagnostics Hldgs Valuation Multiples
Lumos Diagnostics Hldgs trades at 3.8x EV/Revenue multiple, and (10.2x) EV/EBITDA.
EV / Revenue (LTM)
Lumos Diagnostics Hldgs Financial Valuation Multiples
As of October 5, 2026, Lumos Diagnostics Hldgs has market cap of $67M and EV of $58M.
Lumos Diagnostics Hldgs has a P/E ratio of (11.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lumos Diagnostics Hldgs Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Lumos Diagnostics Hldgs Margins & Growth Rates
Lumos Diagnostics Hldgs grew revenue by 60% and EBITDA by 1123% in the last fiscal year.
In the most recent fiscal year, Lumos Diagnostics Hldgs reported gross margin of 60%, EBITDA margin of (3%), and net margin of (38%).
Lumos Diagnostics Hldgs Margins
Lumos Diagnostics Hldgs Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Lumos Diagnostics Hldgs Operational KPIs
Lumos Diagnostics Hldgs' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Lumos Diagnostics Hldgs Competitors
Lumos Diagnostics Hldgs competitors include Austco Healthcare, Osang Healthcare, Fractyl Health, Myomo, Medicalgorithmics, iNtRON Biotechnology, RenovoRx, Meta Biomed, Daxor and Saluda Medical.
Most Lumos Diagnostics Hldgs public comparables operate across Medical Devices, Diagnostics & Genomics, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $65M | $11M | 0.9x | 0.8x | 5.2x | 5.3x | |||
| $95M | $8M | 0.7x | - | 8.2x | - | |||
| - | ($141M) | - | - | (0.6x) | (1.0x) | |||
| $41M | ($13M) | 1.7x | 1.6x | (5.6x) | (9.8x) | |||
| $8M | ($1M) | 8.8x | 6.2x | (54.2x) | 61.2x | |||
| $4M | ($6M) | 9.6x | - | (7.0x) | - | |||
| $1M | ($12M) | 55.4x | 19.3x | (5.4x) | - | |||
| $76M | $15M | 1.0x | 1.1x | 5.3x | 2.0x | |||
This data is available for Pro users. Sign up to see all Lumos Diagnostics Hldgs competitors and their valuation data. Start Free Trial | ||||||||
Lumos Diagnostics Hldgs VC Funding History
Before going public, Lumos Diagnostics Hldgs raised $40M in total equity funding, across 3 rounds.
Lumos Diagnostics Hldgs Funding Rounds
Acquisitions by Lumos Diagnostics Hldgs
Lumos Diagnostics Hldgs has acquired 1 company to date.
Last acquisition by Lumos Diagnostics Hldgs was on May 29th 2019. Lumos Diagnostics Hldgs acquired Rapid Pathogen Screening for undisclosed valuation.
Latest Acquisitions by Lumos Diagnostics Hldgs
| Description | Rapid Pathogen Screening is a developer and marketer of point-of-care diagnostic tests for infectious diseases. Florida-headquartered, the company produces rapid tests for conjunctivitis pathogens like adenovirus and Streptococcus, deliverable in 10 minutes without lab equipment. Its patented platform also supports U.S. government contracts for biothreat and nerve agent detection. Founded in 2004, Rapid Pathogen Screening targets clinician offices with high-sensitivity assays for inflammatory conditions. |
| HQ Country | |
| HQ City | Sarasota, FL |
| Deal Date | 29 May 2019 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Lumos Diagnostics Hldgs acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lumos Diagnostics Hldgs
| When was Lumos Diagnostics Hldgs founded? | Lumos Diagnostics Hldgs was founded in 2018. |
| Where is Lumos Diagnostics Hldgs headquartered? | Lumos Diagnostics Hldgs is headquartered in United States. |
| How many employees does Lumos Diagnostics Hldgs have? | As of today, Lumos Diagnostics Hldgs has over 110 employees. |
| Is Lumos Diagnostics Hldgs publicly listed? | Yes, Lumos Diagnostics Hldgs is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Lumos Diagnostics Hldgs? | Lumos Diagnostics Hldgs trades under LDX ticker. |
| When did Lumos Diagnostics Hldgs go public? | Lumos Diagnostics Hldgs went public in 2021. |
| Who are competitors of Lumos Diagnostics Hldgs? | Lumos Diagnostics Hldgs main competitors include Austco Healthcare, Osang Healthcare, Fractyl Health, Myomo, Medicalgorithmics, iNtRON Biotechnology, RenovoRx, Meta Biomed, Daxor, Saluda Medical. |
| What is the current market cap of Lumos Diagnostics Hldgs? | Lumos Diagnostics Hldgs' current market cap is $67M. |
| What is the current revenue of Lumos Diagnostics Hldgs? | Lumos Diagnostics Hldgs' last 12 months revenue is $15M. |
| What is the current revenue growth of Lumos Diagnostics Hldgs? | Lumos Diagnostics Hldgs revenue growth (NTM/LTM) is 56%. |
| What is the current EV/Revenue multiple of Lumos Diagnostics Hldgs? | Current revenue multiple of Lumos Diagnostics Hldgs is 3.8x. |
| Is Lumos Diagnostics Hldgs profitable? | No, Lumos Diagnostics Hldgs is not profitable. |
| What is the current EBITDA of Lumos Diagnostics Hldgs? | Lumos Diagnostics Hldgs has negative EBITDA and is not profitable. |
| What is Lumos Diagnostics Hldgs' EBITDA margin? | Lumos Diagnostics Hldgs' last 12 months EBITDA margin is (37%). |
| What is the current EV/EBITDA multiple of Lumos Diagnostics Hldgs? | Current EBITDA multiple of Lumos Diagnostics Hldgs is (10.2x). |
| What is the current FCF of Lumos Diagnostics Hldgs? | Lumos Diagnostics Hldgs' last 12 months FCF is ($4M). |
| What is Lumos Diagnostics Hldgs' FCF margin? | Lumos Diagnostics Hldgs' last 12 months FCF margin is (28%). |
| What is the current EV/FCF multiple of Lumos Diagnostics Hldgs? | Current FCF multiple of Lumos Diagnostics Hldgs is (13.6x). |
| How many companies Lumos Diagnostics Hldgs has acquired to date? | As of October 2026, Lumos Diagnostics Hldgs has acquired 1 company. |
| What was the largest acquisition by Lumos Diagnostics Hldgs? | None of the M&A deals Lumos Diagnostics Hldgs has completed have disclosed valuations. |
| What companies Lumos Diagnostics Hldgs acquired? | Lumos Diagnostics Hldgs acquired Rapid Pathogen Screening. |
| In how many companies Lumos Diagnostics Hldgs has invested to date? | Lumos Diagnostics Hldgs hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Lumos Diagnostics Hldgs
Lists including Lumos Diagnostics Hldgs
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




